A long-term complication of obesity is the development of type 2 diabetes (T2D). Patients with T2D have been described as having epigenetic modifications. Epigenetics is the post-transcriptional modification of DNA or associated factors containing genetic information. These environmentally-influenced modifications, maintained during cell division, cause stable changes in gene expression. Epigenetic modifications of T2D are DNA methylation, acetylation, ubiquitylation, SUMOylation, and phosphorylation at the lysine residue at the amino terminus of histones, affecting DNA, histones, and non-coding RNA. DNA methylation has been shown in pancreatic islets, adipose tissue, skeletal muscle, and the liver. Furthermore, epigenetic changes have been observed in chronic complications of T2D, such as diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy. Recently, a new drug has been developed which acts on bromodomains and extraterminal (BET) domain proteins, which operate like epigenetic readers and communicate with chromatin to make DNA accessible for transcription by inhibiting them. This drug (apabetalone) is being studied to prevent major adverse cardiovascular events in people with T2D, low HDL cholesterol, chronic kidney failure, and recent coronary events. This review aims to describe the relationship between obesity, long-term complications such as T2D, and epigenetic modifications and their possible treatments.
Obesity is a pathology whose incidence is increasing throughout the world. There are many pathologies associated with obesity. In recent years, the influence of the microbiota on both health and pathological states has been known. There is growing information related to changes in the microbiome and obesity, as well as its associated pathologies. Changes associated with age, exercise, and weight changes have been described. In addition, metabolic changes associated with the microbiota, bariatric surgery, and fecal matter transplantation are described. In this review, we summarize the biology and physiology of microbiota in obese patients, its role in the pathophysiology of several disorders associated, and the emerging therapeutic applications of prebiotics, probiotics, and fecal microbiota transplantation.
Algunos trabajadores mantienen estilos de vida no saludables que los hace propensos a tener un alto riesgo de diabetes tipo 2 (DT2). El presente estudio tuvo como objetivo evaluar el riesgo de DT2 (RDT2) en personal administrativo y docente de una universidad ecuatoriana y factores asociados. Estudio de corte transversal que evaluó el RDT2 según FINDRISC. Se consideró RDT2 alto si la puntuación ≥12 puntos. Se analizaron aspectos sociodemográficos, hábitos nocivos y saludables; se midieron el índice de masa corporal (IMC), el perímetro abdominal (PA) y la tensión arterial (TA). Se evaluaron las razones de prevalencia bruta (RPB) y ajustada (RPA) para identificar factores asociados con RDT2. De 311 participantes, edad media de 41,02 años (DE 10,1), 58,2% mujeres y 41,8% hombres. La prevalencia de RDT2 elevada fue mayor en mujeres respecto a varones (38,1% frente a 32,3%) y aumentó en mayores de 40 años [RPA 1.55 (1.11-2.15)], personas casadas [RPA 1.49 (1.07-2.05)], aquellos con actividad física moderada o menor [RPA 1.55 (1.11-2.15)], y en aquellos con PA elevado [RPA 2,41 (1,33 - 4,36)]. La edad, la baja actividad física y el PA, fueron factores asociados con una mayor prevalencia de RDT2. Se deben promover estilos de vida saludables, para incrementar la actividad física y disminuir el PA en trabajadores, para reducir el riesgo de DT2. Palabras claves: Diabetes Mellitus tipo 2, Estilos de Vida, Factores de Riesgo, Salud Laboral
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.